PharmacoEconomics Article Authors Discuss 8 Recommendations for CEAs in Diagnostic Assessments

An article published in PharmacoEconomics details eight recommendations regarding how cost-effectiveness analyses (CEAs) are used in diagnostics. The researchers call for clear reporting of patients’ symptoms and the diagnostic algorithms used. They also call for the use of quality-adjusted life-years (QALYs) or disability-adjusted life-years (DALYs), noting an overreliance on short-term outcomes.

“The recommendations provided in this paper can be used to improve the design and reporting CEAs in the field of diagnostics, resulting in well-informed reimbursement decisions by policy makers.” Read more here.

(Source Simon van der Pol et al., PharmacoEconomics, 11/1/21)